Alpha¹ by KaimenConfidential

Kaimen Rigor review

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators.

DOI: 10.1056/nejmoa2507109
Record issued: 2026-08-10
Engine: 7.29.0
Exported: 2026-09-22

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/846b932d-7ddc-40f5-8e03-1d2ab692dce0 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Biggest issues

01Key resources not identified
highDisclosurereviewer-assessedFull detail
The investigational product (baxdrostat) is not fully identified (no manufacturer/source, formulation) and the statistical software version is not reported.
“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily.”
MethodsFind in source
02Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement is provided; the paper does not mention where data or code can be accessed.

Findings by category

01ArithmeticNone found 102OverreachOverstated conclusions 03AuthenticityNone found 204DisclosureReporting gaps 05AvailabilityNone found 06Copyedit10 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 RCT (randomization, blinding, power analysis, ethics, trial registration, and proportional conclusions all well handled) with strong biological-variable and transparency reporting. The primary weaknesses are the complete absence of a data availability statement, incomplete identification of the investigational product and software version, and threshold-only primary p-values; the copyedit pass found only minor typographical and clarity issues.

Three independent reviewer runs plus a copyedit pass and specialized verification components were synthesized. Statistics coverage was limited to the 6 tests with machine-verifiable test statistics or effect estimates (all consistent); threshold-only p-values, resampling-based, and exact p-values could not be verified and are not evidence of correctness. The citation check found 0 retracted and 0 not-found references among 25 checked; the reproducibility check found 0 dead/inconsistent links of 4; the claim audit found 0 under-evidenced claims. Reviewers diverged on three dimensions (ethical approvals, key resources, statistical analysis); each divergence is resolved with explicit reasoning in the dimension details.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2, 3
Primary outcome p-value for baxdrostat 1 mg vs placebo
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001)”
Find in source
Taken as given: The estimate is the least-squares mean difference; The 95% CI is two-sided and based on a normal approximation; The CI is symmetric on the linear scale
Method: p from estimate and 95% CI using the pCI function (two-sided, log=0)
How we recomputed it: pCI(-8.7, -11.5, -5.8, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2, 3
Primary outcome p-value for baxdrostat 2 mg vs placebo
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively.”
Find in source
Taken as given: The estimate is the least-squares mean difference; The 95% CI is two-sided and based on a normal approximation; The CI is symmetric on the linear scale
Method: p from estimate and 95% CI using the pCI function (two-sided, log=0)
How we recomputed it: pCI(-9.8, -12.6, -7.0, 0)
CONSISTENTreported p = .002 · recomputed p = .002Reviewers 1, 2
Secondary outcome p-value for randomized withdrawal period
“LS mean placebo-corrected difference (95% CI) – mmHg | – | NA | –5.1 (–8.3 to –1.9) | P value | – | NA | 0.0016”
Find in source
Taken as given: The estimate is the least-squares mean difference; The 95% CI is two-sided and based on a normal approximation; The CI is symmetric on the linear scale
Method: p from estimate and 95% CI using the pCI function (two-sided, log=0)
How we recomputed it: pCI(-5.1, -8.3, -1.9, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 3
Secondary outcome p-value for seated DBP change baxdrostat 1 mg vs placebo
“LS mean placebo-corrected difference (95% CI) – mmHg | – | –3.3 (–5.2 to –1.4) | –3.9 (–5.7 to –2.0) | P value | – | 0.0008 | <0.0001”
Find in source
Taken as given: The estimate is the least-squares mean difference; The 95% CI is two-sided and based on a normal approximation; The CI is symmetric on the linear scale
Method: p from estimate and 95% CI using the pCI function (two-sided, log=0)
How we recomputed it: pCI(-3.3, -5.2, -1.4, 0)
CONSISTENTreported p = .002 · recomputed p = .002Reviewer 3
Secondary endpoint: randomized withdrawal, baxdrostat 2 mg vs placebo, difference -5.1 (95% CI -8.3 to -1.9), P=0.0016
“LS mean placebo-corrected difference (95% CI) – mmHg | – | NA | –5.1 (–8.3 to –1.9) | P value | – | NA | 0.0016”
Find in source
Taken as given: The 95% CI is two-sided and based on a normal approximation; The estimate is the least-squares mean difference from ANCOVA
Method: pCI function using the estimate and 95% CI to compute a two-sided p-value from a normal approximation
How we recomputed it: pCI(-5.1, -8.3, -1.9, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 3
Secondary endpoint: seated DBP change, baxdrostat 2 mg vs placebo, difference -3.9 (95% CI -5.7 to -2.0), P<0.0001
“LS mean placebo-corrected difference (95% CI) – mmHg | – | –3.3 (–5.2 to –1.4) | –3.9 (–5.7 to –2.0) | P value | – | 0.0008 | <0.0001”
Find in source
Taken as given: The 95% CI is two-sided and based on a normal approximation; The estimate is the least-squares mean difference from ANCOVA
Method: pCI function using the estimate and 95% CI to compute a two-sided p-value from a normal approximation
How we recomputed it: pCI(-3.9, -5.7, -2.0, 0)

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

partialReviewers 1, 2, 3
The BP lowering effects of baxdrostat were consistent with those reported for lorundrostat.
The paper cites a phase 3 trial of lorundrostat with a similar placebo-adjusted reduction, but the comparison is based on a single cited trial and not a formal meta-analysis.
Evidence: Discussion: 'The BP lowering effects of baxdrostat in our study were consistent with those reported for the aldosterone synthase inhibitor lorundrostat. In a phase 3 trial in patients with uncontrolled and resistant hypertension, the placebo-adjusted reduction in office SBP with lorundrostat 50 mg was –9.1 mmHg (95% CI, –13.3 to –4.9) at week 6 (primary endpoint).'
“The BP lowering effects of baxdrostat in our study were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.”
Discussion ¶3Find in source
partialReviewer 1
The slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis.
The paper speculates about mechanisms but does not present direct evidence for sodium homeostasis changes; it is based on observed BP changes during withdrawal and aldosterone/PRA levels.
Evidence: Discussion: 'We speculate that the slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis. Other possible mechanisms include inhibition or reversal of aldosterone's deleterious effects on the vasculature and sympathetic nervous system activity.'
We speculate that the slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis.
Discussion ¶4reviewer’s wording
supportedReviewer 1
Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo.
The primary endpoint data show statistically significant reductions with both doses, supporting the claim.
Evidence: Table 2: LS mean placebo-corrected differences –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) for 1 mg and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001) for 2 mg.
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”
Table 2Find in source
supportedReviewers 2, 3
Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in patients with uncontrolled or resistant hypertension.
The primary endpoint shows statistically significant reductions with both doses, with LS mean differences of -8.7 and -9.8 mmHg and p<0.0001.
Evidence: Table 2 and Figure 1: LS mean placebo-corrected differences and 95% CIs.
“At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% confidence interval [CI], –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8). Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively.”
Table 2Find in source
supportedReviewer 2
Baxdrostat is a highly selective, potent aldosterone synthase inhibitor with a plasma half-life of approximately 30 hours.
This claim is a description of the drug's properties, likely based on prior pharmacology studies. The paper references earlier studies (references 6,7) in the Introduction.
Evidence: Introduction, paragraph 2: 'Baxdrostat is a highly selective, potent aldosterone synthase inhibitor with a plasma half-life of approximately 30 hours, allowing once daily administration.'
“Baxdrostat is a highly selective, potent aldosterone synthase inhibitor with a plasma half-life of approximately 30 hours, allowing once daily administration.”
Introduction ¶2Find in source
supportedReviewer 3
Baxdrostat was generally safe and well-tolerated with a low incidence of serious adverse events and hyperkalemia leading to discontinuation.
Safety data show low rates of serious AEs, mostly mild AEs, and low discontinuation due to hyperkalemia, though hyperkalemia and hyponatremia are more common with baxdrostat.
Evidence: Table 3: serious AEs: 1.9%, 3.4%, 2.7% in baxdrostat 1 mg, 2 mg, placebo; hyperkalemia leading to discontinuation: 0.8%, 1.5%, 0%.
During part 1, one death occurred in the placebo group. Serious AEs occurred in 5 (1.9%), 9 (3.4%) and 7 (2.7%) participants receiving baxdrostat 1 mg, baxdrostat 2 mg and placebo, respectively.
Table 3reviewer’s wording
supportedReviewer 3
The study provides additional data, including the impact of a randomized treatment withdrawal.
The randomized withdrawal period (part 3) shows a significant difference favoring baxdrostat 2 mg over placebo, supporting the drug's efficacy.
Evidence: Results, Secondary End Points: 'LS mean placebo-corrected difference of –5.1 mmHg (95% CI, –8.3 to –1.9; P=0.0016)'
Secondary end point – change in seated-SBP from randomized withdrawal period baseline (week 24) to week 32 (baxdrostat 2 mg versus placebo) | ... | LS mean placebo-corrected difference (95% CI) – mmHg | – | NA | –5.1 (–8.3 to –1.9)
Resultsreviewer’s wording

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

ADEQUATESurrogate endpoint
Primary endpoint is seated office SBP, a validated clinical measure. Target engagement shown via aldosterone reduction and link to clinical outcomes cited.
“change in seated-SBP from baseline to week 12... estimated treatment differences... –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (–12.6 to –7.0; P<0.0001). Previous studies have shown that 5–10 mmHg reductions in SBP are associated with reduced risk of cardiovascular disease and death.”
Find in source
ADEQUATEEffect size
Placebo-adjusted SBP reduction of 8.7-9.8 mmHg, which is within the clinically meaningful range cited by the authors.
“estimated treatment differences... –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (–12.6 to –7.0; P<0.0001)”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

2 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed

Eight Dimensions6 pass · 2 fail

Prior work is cited (BrigHTN, HALO, and a primary aldosteronism study), including both positive and negative results. The rationale links aldosterone dysregulation to hard-to-control hypertension and discusses shortcomings of MRAs. The paper explicitly states that the phase 3 trial addresses limitations of shorter-duration and narrower-population prior trials.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior work (phase 2 trials), explaining the rationale for aldosterone synthase inhibition, and addressing limitations of prior studies.

Evidence

“In the 12-week phase 2 BrigHTN trial in patients with resistant hypertension, baxdrostat reduced seated office systolic blood pressure (seated-SBP) compared with placebo. However, in a phase 2 trial (HALO) in patients with uncontrolled hypertension, baxdrostat failed to show a difference in change from baseline in seated-SBP at week 8 versus placebo.”

Introduction ¶2Find in source

“An alternative therapeutic approach is direct inhibition of aldosterone synthase, which catalyzes the final three steps in aldosterone biosynthesis.”

Introduction ¶1Find in source

“Here, we report the results of a longer-term, phase 3 trial assessing the efficacy and safety of baxdrostat in a broader population of patients with uncontrolled or resistant hypertension.”

Introduction ¶3Find in source

PASSReviewer 2· 95% conf

The paper establishes a strong scientific foundation by citing prior research on aldosterone dysregulation, phase 2 trials, and providing a logical rationale for aldosterone synthase inhibition.

Evidence

paraphrase[Abstract and Introduction, paragraph 1-2]

“Inappropriately elevated aldosterone production relative to patient sodium status is a key driver of hard-to-control (uncontrolled and resistant) hypertension and hypertension-mediated organ damage.”

“However, in a phase 2 trial (HALO) in patients with uncontrolled hypertension, baxdrostat failed to show a difference in change from baseline in seated-SBP at week 8 versus placebo.”

Introduction ¶2Find in source

“Here, we report the results of a longer-term, phase 3 trial assessing the efficacy and safety of baxdrostat in a broader population of patients with uncontrolled or resistant hypertension.”

IntroductionFind in source

PASSReviewer 3· 95% conf

The paper clearly establishes the scientific foundation by citing prior research, providing a logical rationale, and addressing limitations of prior work.

Evidence

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 1]

“Here, we report the results of a longer-term, phase 3 trial assessing the efficacy and safety of baxdrostat in a broader population of patients with uncontrolled or resistant hypertension.”

Introduction ¶2Find in source

The trial is randomized 1:1:1 with stratification by hypertension status and baseline SBP. It is double-blind with a placebo run-in. A power analysis with 98% power and a 6 mmHg difference is provided. Inclusion/exclusion criteria are detailed. Missing data are handled by multiple imputation with retrieved dropout and washout methods. The unit of randomization is participants. For a clinical trial, all applicable sub-criteria are adequately reported.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study design includes randomization, blinding, a power analysis, inclusion/exclusion criteria, and missing-data handling, though the randomization method and blinding stages are not fully detailed.

Evidence

“Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”

MethodsFind in source

“It was estimated that 720 participants would need to be randomized to achieve 98% power to detect a mean (standard deviation [SD]) difference of 6 (15) mmHg for change from baseline in seated-SBP at week 12 in favor of baxdrostat versus placebo using a two-sample t-test with a two-sided significance level of 0.025.”

Statistical analysisFind in source

“Missing data at week 12 following treatment discontinuation were imputed using a multiple imputation retrieved dropout method and missing data at week 12 following initiation of rescue medication were imputed using a multiple imputation washout method.”

Statistical analysisFind in source

PASSReviewer 2· 100% conf

The study design is rigorous with adequate randomization, blinding, power analysis, inclusion/exclusion criteria, and handling of missing data.

Evidence

“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily. Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”

Methods ¶3Find in source

Statistical analysis ¶2Find in source

paraphrase[Methods, Statistical Analyses, paragraph 2 and Table 2 footnote]

“Missing data at week 12 were imputed using multiple imputation retrieved dropout method for treatment discontinuation and washout method for rescue medication initiation.”

PASSReviewer 3· 95% conf

The study design is rigorous with adequate blinding, power analysis, inclusion criteria, and missing data handling, but the randomization method is not explicitly described.

Evidence

Methods ¶3Find in source

“BaxHTN is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial”

Methods ¶1Find in source

Statistical analysis ¶2Find in source

Table 1 reports age, sex (male %), race, ethnicity, BMI, eGFR, diabetes status, and baseline blood pressure. Both sexes are enrolled, so sex_justified is not applicable. Age and weight (via BMI) are given. Demographics are comprehensive. All applicable sub-criteria are adequately reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Sex, age, BMI, health status, and demographics are reported in Table 1, meeting the criteria for a human trial.

Evidence

“Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”

Table 1Find in source

“Age – yrs | 61.9±11.6 | 59.8±11.8 | 61.8±11.7”

Table 1Find in source

paraphrase[Table 1]

“Race or ethnic group – no. (%) | White | 167 (63.3) | 165 (62.5) | 168 (63.2)”

PASSReviewer 2· 100% conf

Biological variables including sex, age, weight, and demographics are adequately reported in Table 1.

Evidence

paraphrase[Results, Table 1]

“Male sex – no. (%) Placebo 162 (61.4), Baxdrostat 1 mg 169 (64.0), Baxdrostat 2 mg 163 (61.3)”

paraphrase[Results, Table 1]

“Age – yrs 61.9±11.6, 59.8±11.8, 61.8±11.7; Body-mass index 31.1±6.0, 31.5±6.4, 31.2±6.2”

paraphrase[Results, Table 1]

“White 167 (63.3), 165 (62.5), 168 (63.2); Hispanic or Latino 38 (14.4), 27 (10.2), 39 (14.7)”

PASSReviewer 3· 95% conf

Biological variables and subject characteristics are comprehensively reported in Table 1, including sex, age, race, BMI, and health status.

Evidence

“Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”

Table 1Find in source

paraphrase[Table 1]

“Age – yrs | 61.9±11.6 | 59.8±11.8 | 61.8±11.7 | Body-mass index | 31.1±6.0 | 31.5±6.4 | 31.2±6.2 | Diabetes – no. (%) | 110 (41.7) | 83 (31.4) | 110 (41.4)”

paraphrase[Table 1]

“White | 167 (63.3) | 165 (62.5) | 168 (63.2) | Black | 15 (5.7) | 23 (8.7) | 21 (7.9) | Asian | 72 (27.3) | 65 (24.6) | 72 (27.1)”

The paper explicitly states that the trial was conducted in accordance with the Declaration of Helsinki, ICH-GCP guidelines, and applicable laws. It mentions that IRBs/ECs approved the protocol and that all participants provided written informed consent. The trial is registered on ClinicalTrials.gov. All applicable sub-criteria are adequately reported.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper reports IRB/ethics committee approval, written informed consent, and regulatory compliance, all adequate.

Evidence

paraphrase[Methods, Trial Design]

“Institutional Review Boards/Independent Ethics Committees approved the protocol (available at nejm.org)”

“all participants provided written, informed consent before enrollment.”

MethodsFind in source

“the trial was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference for Harmonization Good Clinical Practice guidelines, and applicable laws and regulations.”

MethodsFind in source

PASSReviewer 2· 100% conf

Ethical approvals are clearly stated: named IRB/EC approval, written informed consent, and compliance with Declaration of Helsinki and ICH-GCP.

Evidence

paraphrase[Methods, Trial Design, Population, and Procedures, paragraph 1]

“Institutional Review Boards/Independent Ethics Committees approved the protocol (available at nejm.org), and all participants provided written, informed consent before enrollment.”

Methods ¶1Find in source

“all participants provided written, informed consent before enrollment.”

Methods ¶1Find in source

WARNReviewer 3· 90% conf

Ethical approval is mentioned but the specific IRB/IEC is not named; informed consent and regulatory compliance are adequately reported.

Evidence

“Institutional Review Boards/Independent Ethics Committees approved the protocol (available at nejm.org”

Methods ¶1Find in source

“all participants provided written, informed consent before enrollment.”

Methods ¶1Find in source

Baxdrostat is named but not identified with manufacturer, lot number, or formulation. The dose and regimen are given. SAS software is named but without version. These are the only applicable resources, and both are inadequately reported.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

The investigational product (baxdrostat) is not fully identified (no manufacturer/source, formulation) and the statistical software version is not reported.

Evidence

“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily.”

MethodsFind in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (baxdrostat) is adequately identified with dose and regimen, but the source is implied rather than explicitly stated. Statistical software is identified.

Evidence

“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily.”

Methods ¶3Find in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysis ¶2Find in source

paraphrase[Methods, Trial Design, Population, and Procedures, paragraph 1]

“Funded by AstraZeneca, the trial executive committee and AstraZeneca designed BaxHTN.”

FAILReviewer 3· 80% conf

The investigational product (baxdrostat) is not identified with manufacturer/source, and statistical software lacks a version number, resulting in no applicable sub-criterion being adequate.

Evidence

absence[Methods, paragraph 1 and throughout]

The drug baxdrostat is not identified with manufacturer or source.

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysis ¶2Find in source

The primary analysis uses ANCOVA with treatment and hypertension status as factors and baseline SBP as covariate. Exact p-values (e.g., <0.0001, 0.0016) and 95% CIs are reported. The sample size calculation is provided. Missing data are imputed. The software is SAS. Data are presented in tables and figures with per-group n and error bars. No arithmetic implausibilities were detected. For a large clinical trial, all applicable sub-criteria are adequately reported.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Most statistical criteria are met, but the primary p-values are reported as thresholds (<0.0001) rather than exact values, and software version is missing.

Evidence

“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”

ResultsFind in source

“At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% confidence interval [CI], –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8).”

ResultsFind in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysisFind in source

PASSReviewer 2· 100% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, software identification, and adequate data presentation. Assumptions are handled by standard methods.

Evidence

“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”

Statistical analysis ¶1Find in source

“Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively.”

Results ¶1Find in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysis ¶2Find in source

PASSReviewer 3· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and data presentation is adequate. Exact p-values are not provided for the primary endpoint (reported as threshold), and software version is missing, but overall the analysis meets the passing threshold.

Evidence

“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”

Statistical analysis ¶1Find in source

paraphrase[Results, Primary End Point]

“Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”

paraphrase[Results, Primary End Point]

“–8.7 mmHg (95% CI, –11.5 to –5.8)”

The paper mentions that data were collected and analyzed by AstraZeneca but does not include a statement on data availability, repository deposit, or code sharing. For this clinical trial, a data availability statement is required and is absent.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 95% conf

No data availability statement is provided; the paper does not mention where data or code can be accessed.

Evidence

absence[Methods, Trial Design]

No data availability statement

FAILReviewer 2· 95% conf

No data availability statement is present in the manuscript. There is no mention of repository deposit, accession numbers, or code sharing. This is a significant omission for a clinical trial.

Evidence

absence[Entire manuscript]

No data availability statement is found.

FAILReviewer 3· 90% conf

No data availability statement is present. The trial registration and protocol URL are provided, but a data access statement is missing, and the other sub-criteria are not applicable.

Evidence

absence[Entire paper]

No data availability statement is found in the paper.

Methods are comprehensive. The trial is registered (NCT06034743). All pre-specified endpoints are reported with positive and secondary results. Limitations are discussed (ambulatory BP subset, demographics, adherence). Conclusions are proportional to the evidence. Funding and conflicts of interest are disclosed. The only missing element is an explicit mention of a reporting guideline (e.g., CONSORT).

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper reports methods, trial registration, outcomes, limitations, proportional conclusions, and funding, but does not reference a reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743) .”

AbstractFind in source

paraphrase[Discussion]

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants. However, ambulatory BP is being measured in the ongoing 12-week Bax24 study ( https://clinicaltrials.gov/study/NCT06168409 ), to be reported subsequently. There was a lower proportion of women and Black participants with hypertension enrolled than observed in the real world...”

“Disclosure forms provided by the authors are available with the full text of this article at NEJM.org (https://nejm.org/) .”

DiscussionFind in source

PASSReviewer 2· 95% conf

The manuscript is largely transparent with detailed methods, trial registration, all outcomes reported, limitations discussed, and funding/COI statements. However, it does not reference a specific reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”

AbstractFind in source

paraphrase[Discussion, paragraph 7]

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants. ... There was a lower proportion of women and Black participants with hypertension enrolled than observed in the real world”

paraphrase[Discussion, last paragraph; Disclosure forms]

“Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.”

PASSReviewer 3· 95% conf

The manuscript is generally transparent with trial registration, limitations discussion, proportional conclusions, and funding disclosure, but it does not reference a reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”

AbstractFind in source

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants. However, ambulatory BP is being measured in the ongoing 12-week Bax24 study”

Discussion ¶5Find in source

paraphrase[Funding, Disclosure forms]

“Funded by AstraZeneca. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.”

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT06034743

ClinicalTrials.gov

NCT06168409

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 24 verified — 1 no DOI (shown, not verified).

NO DOI
Baxdrostat in patients with uncontrolled hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

4 data/code links checked; 3 live.

datahttps://clinicaltrials.gov/ct2/show/NCT06034743LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/study/NCT06034743LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://nejm.org/UNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.
datahttps://clinicaltrials.gov/study/NCT06168409LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

10 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 10 minor suggestions below.

10 copyedit issues flagged: mostly typo, clarity, consistency.

MINORtypoResults, Safety
“Hyperkaemia (potassium levels >5.5mmol/l) occurred in 16/262 (6.1%), 29/261 (11.1%) and 1/260 (0.4)”
→ Change 'Hyperkaemia' to 'Hyperkalemia' and add closing parenthesis after '0.4'.
Typo in the word 'Hyperkalemia' and missing parenthesis.
MINORclarityMethods, Trial Design
“The study consisted of four sequential parts over a total duration of 52 weeks ().”
→ Remove stray parentheses or add a citation/reference.
Empty parentheses likely indicate a missing figure or reference.
MINORconsistencyResults, Safety
“The percent change in eGFR >30% that occurred on treatment was 12.6%, 15.6% and 1.5% and, ≥30% was 12.6%, 15.6% and 1.5% and ≥50% in 0.4, 1.5 and 1.1%, in participants receiving baxdrostat 1 and 2 mg, and placebo, respectively.”
→ Rephrase for clarity: 'The percent change in eGFR >30% was 12.6%, 15.6%, and 1.5% for baxdrostat 1 mg, 2 mg, and placebo, respectively; ≥50% changes occurred in 0.4%, 1.5%, and 1.1% of participants.'
The sentence is repetitive and confusing.
MINORtypoResults, Safety, paragraph 2
“Hyperkaemia (potassium levels >5.5mmol/l) occurred in 16/262 (6.1%)”
→ Change 'Hyperkaemia' to 'Hyperkalemia'.
Standard spelling is 'hyperkalemia'.
MINORtypoResults, Table 3, row for 'Hyperkaemia'
“Hyperkaemia”
→ Change to 'Hyperkalemia'.
Same typo in table header.
MINORtypoAbstract, end of sentence
“Other; BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743) .) Issue date 2025 Oct 9.”
→ Remove stray period and space before closing parenthesis. Change to: 'Other; BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743). Issue date 2025 Oct 9.'
The abstract has an extra period before the issue date.
MINORtypoSafety results, paragraph 2
“Hyperkaemia (potassium levels >5.5mmol/l) occurred in 16/262 (6.1%), 29/261 (11.1%) and 1/260 (0.4)”
→ Change 'Hyperkaemia' to 'Hyperkalemia' and add a closing parenthesis after '0.4'.
Misspelling of hyperkalemia and missing closing parenthesis.
MINORconsistencySafety results, paragraph 2
“The percent change in eGFR >30% that occurred on treatment was 12.6%, 15.6% and 1.5% and, ≥30% was 12.6%, 15.6% and 1.5% and ≥50% in 0.4, 1.5 and 1.1%”
→ Rephrase for clarity: 'The percent change in eGFR >30% that occurred on treatment was 12.6%, 15.6% and 1.5% in the baxdrostat 1 mg, baxdrostat 2 mg, and placebo groups, respectively. The corresponding values for ≥50% were 0.4%, 1.5%, and 1.1%.'
Redundant and confusing phrasing.
MINORpunctuationDiscussion, paragraph 1
“In patients with uncontrolled or resistant hypertension, the addition of 1 mg or 2 mg daily doses of baxdrostat to background antihypertensive medication led to placebo-adjusted reductions in seated-SBP of 8.7 mmHg and 9.8 mmHg, respectively, after 12 weeks of treatment.”
→ Consider adding a comma after 'respectively' or rephrasing to avoid a run-on sentence.
The sentence is clear but could be slightly restructured.
MINORclaritySafety results, paragraph 3
“The mean change in estimated glomerular filtration rate (eGFR) from baseline to week 12 was –7.0 ml/min/1.73m 2 (SD 12.8) and –6.9 (12.4) ml/min/1.73m 2 in participants receiving baxdrostat 1 and 2 mg, respectively, and –0.1 (8.6) ml/min/1.73m 2 in those receiving placebo.”
→ Add 'mL/min/1.73 m^2' for clarity and consistency.
The units are abbreviated inconsistently.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and its headline conclusions are supported by the reported effect sizes and CIs, with no detected numerical inconsistencies and no problematic citations. An informed reader should weigh two consequential transparency gaps that warrant a journal-level clarification or correction: the absence of any data availability statement (limiting independent verification) and the incomplete identification of the investigational product's source and software version; the threshold-only primary p-values and minor copyedit issues are lower-weight. The finding is robust enough to stand, but the data-sharing gap is the most consequential item for a reader to weigh.

1.
HIGHdata code
Add a data availability statement to the published article (or as a journal correction) specifying how de-identified individual participant data can be requested — e.g., via a managed-access platform such as Vivli or a named data-access committee with conditions and timeline.
The paper reports no data availability statement at all, which is the most consequential transparency gap in an otherwise well-reported trial and directly limits independent verification of the results.
2.
HIGHrigor
In the Methods (Trial Design), explicitly identify the manufacturer/source and formulation of baxdrostat (and placebo), e.g., 'baxdrostat tablets were supplied by AstraZeneca as 1 mg and 2 mg oral tablets'.
The investigational product is a scored resource for a drug trial and is currently identified only by name, with the source merely implied through the funding statement.
3.
HIGHstatistics
Add the SAS software version used for the analyses (e.g., 'SAS version 9.4') to the Methods Statistical Analyses section.
Two reviewers flagged the missing software version, which is needed for reproducibility of the statistical analyses.
4.
HIGHstatistics
Report exact p-values for the primary endpoint (or add a note that the printed 'P<0.0001' values are the exact values as computed) rather than threshold-only values.
Threshold-only p-values are a form of imprecise reporting that cannot be machine-verified and were the basis of the statistical-analysis warn.
5.
MEDIUMreporting
Reference adherence to the CONSORT 2010 reporting guideline for randomized trials in the Methods or as a supplementary checklist.
All three reviewers noted that no reporting guideline is referenced, a minor but standard transparency element for an RCT.
6.
MEDIUMrigor
Specify the method of random sequence generation (e.g., centralized computer-generated randomization via an interactive web-response system) in the Trial Design section.
Two reviewers flagged that the randomization method is described only as stratified, without the sequence-generation procedure.
7.
MEDIUMcopyedit
Fix the misspelling 'Hyperkaemia' to 'Hyperkalemia' in the Results Safety text and in Table 3.
The standard clinical term is misspelled in multiple locations, which detracts from the published record.
8.
MEDIUMcopyedit
Add the missing closing parenthesis after '0.4' in the hyperkalemia incidence sentence ('...and 1/260 (0.4)').
The parenthetical percentage is left unclosed, an obvious typographical error in the Safety results.
9.
MEDIUMcopyedit
Rewrite the confusing, repetitive eGFR sentence in the Safety results (the '>30% ... ≥30% ... ≥50%' phrasing) into a clear per-group statement.
The current phrasing is redundant and hard to parse, obscuring the reported eGFR change categories.
10.
LOWcopyedit
Remove the stray period before the issue date in the Abstract ('...NCT06034743) .) Issue date 2025 Oct 9.').
An extra period and space appear before the closing parenthesis and issue date.
11.
LOWcopyedit
Remove the empty parentheses after '52 weeks ()' in the Methods Trial Design section, or insert the intended reference/figure.
Empty parentheses indicate a missing citation or figure reference.
12.
LOWcopyedit
Standardize the eGFR unit notation to 'mL/min/1.73 m²' throughout the Safety results.
The units are abbreviated inconsistently across the passage.
13.
LOWethics
Consider naming a central IRB/ethics committee or providing an approval reference in the protocol footnote to strengthen the ethics statement.
One reviewer flagged that no specific committee is named, even though the generic multi-committee statement is standard for a multinational trial.
14.
LOWstatistics
Clarify in the power analysis that the two-sided significance level of 0.025 applies per comparison under the hierarchical testing procedure.
One reviewer suggested clarifying the alpha allocation for the two active-dose comparisons.

Full text (34,763 chars)Analyzed: Aug 10, 2026

RigorReviewer 1

RigorReviewer 2

RigorReviewer 3

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators.

DOI

10.1056/nejmoa2507109

Record issued

2026-08-10

Engine

7.29.0

Exported

2026-09-22